UA104890C2 - Антитіла проти фактора росту нервів (фрн), що мають підвищену стабільність in vivo - Google Patents
Антитіла проти фактора росту нервів (фрн), що мають підвищену стабільність in vivoInfo
- Publication number
- UA104890C2 UA104890C2 UAA201114294A UAA201114294A UA104890C2 UA 104890 C2 UA104890 C2 UA 104890C2 UA A201114294 A UAA201114294 A UA A201114294A UA A201114294 A UAA201114294 A UA A201114294A UA 104890 C2 UA104890 C2 UA 104890C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- ngf
- antibodies
- growth factor
- nerve growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Винахід належить до антитіл проти фактору росту нервів (ФРН), які містять варіабельну область важкого ланцюга, варіабельну область легкого ланцюга та константну область IgG4, причому антитіла демонструють довгий період напіввиведення із сироватки в яванських макаків. Винахід також спрямовано на створення фармацевтичних композицій, що містять антитіла проти ФРН, нуклеїнові кислоти, що кодують антитіла проти ФРН, клітини-хазяїни, що експресують антитіла проти ФРН, і способи застосування антитіл для лікування захворювань або станів, пов'язаних із ФРН.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17522809P | 2009-05-04 | 2009-05-04 | |
US22725109P | 2009-07-21 | 2009-07-21 | |
US23881309P | 2009-09-01 | 2009-09-01 | |
US25231409P | 2009-10-16 | 2009-10-16 | |
PCT/IB2010/001210 WO2010128398A1 (en) | 2009-05-04 | 2010-05-04 | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
Publications (1)
Publication Number | Publication Date |
---|---|
UA104890C2 true UA104890C2 (uk) | 2014-03-25 |
Family
ID=43030513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201114294A UA104890C2 (uk) | 2009-05-04 | 2010-05-04 | Антитіла проти фактора росту нервів (фрн), що мають підвищену стабільність in vivo |
Country Status (31)
Country | Link |
---|---|
US (2) | US8435523B2 (uk) |
EP (1) | EP2448970B1 (uk) |
JP (2) | JP5898064B2 (uk) |
KR (1) | KR20120088550A (uk) |
CN (1) | CN102459337B (uk) |
AR (1) | AR076650A1 (uk) |
AU (1) | AU2010244133B2 (uk) |
BR (1) | BRPI1014445A8 (uk) |
CA (1) | CA2761203A1 (uk) |
CL (1) | CL2011002765A1 (uk) |
CO (1) | CO6470819A2 (uk) |
CR (1) | CR20110629A (uk) |
DK (1) | DK2448970T3 (uk) |
DO (1) | DOP2011000337A (uk) |
EC (1) | ECSP11011502A (uk) |
ES (1) | ES2514319T3 (uk) |
HK (1) | HK1170508A1 (uk) |
HR (1) | HRP20140915T1 (uk) |
IL (1) | IL216128A (uk) |
MX (1) | MX2011011728A (uk) |
NZ (1) | NZ596839A (uk) |
PE (1) | PE20121540A1 (uk) |
PL (1) | PL2448970T3 (uk) |
PT (1) | PT2448970E (uk) |
RU (1) | RU2549679C2 (uk) |
SG (1) | SG175436A1 (uk) |
SI (1) | SI2448970T1 (uk) |
TW (1) | TWI486171B (uk) |
UA (1) | UA104890C2 (uk) |
UY (1) | UY32608A (uk) |
WO (1) | WO2010128398A1 (uk) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
PT2187964E (pt) | 2007-08-10 | 2015-01-14 | Regeneron Pharma | Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
PT2448970E (pt) * | 2009-05-04 | 2014-10-20 | Abbvie Res B V | Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada |
AU2011227335B2 (en) | 2010-03-17 | 2014-11-06 | Abbott Research B.V. | Anti-nerve growth factor (NGF) antibody compositions |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
JP6190723B2 (ja) * | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
WO2012083370A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
ES2704007T3 (es) | 2011-05-06 | 2019-03-13 | Nexvet Australia Pty Ltd | Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos |
US8986952B2 (en) | 2011-08-11 | 2015-03-24 | Astellas Pharma Inc. | Anti-human NGF antibody |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
KR200480634Y1 (ko) | 2015-04-14 | 2016-06-16 | 한전케이피에스 주식회사 | 긴급복구용 윈치의 고정장치 |
CN107614683B (zh) | 2015-05-22 | 2020-12-22 | 安斯泰来制药株式会社 | 新型抗人NGF抗体Fab片段 |
IT201700066486A1 (it) * | 2017-06-15 | 2018-12-15 | Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A | Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche |
CN108623687A (zh) * | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
EP3795176A4 (en) | 2018-05-15 | 2022-01-12 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE |
AU2019250128A1 (en) | 2018-10-15 | 2020-04-30 | Avent Inc. | Compositions, systems, kits, and methods for neural ablation |
WO2020248942A1 (zh) * | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗β-NGF纳米抗体及其应用 |
CN110583625A (zh) * | 2019-09-17 | 2019-12-20 | 深圳大学 | 一种脐带储存液 |
AU2020204105B2 (en) * | 2020-06-19 | 2023-06-08 | Ampsource Biopharma Shanghai Inc. | Anti-human ngf antibodies and methods using same |
US11655292B2 (en) | 2020-06-23 | 2023-05-23 | Ampsource Biopharma Shanghai Inc. | Anti-human NGF antibodies and methods using same |
CN116003590A (zh) * | 2020-08-06 | 2023-04-25 | 熙源安健医药(上海)有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
CN114729330A (zh) | 2021-07-30 | 2022-07-08 | 成都优洛生物科技有限公司 | 一种重组cho细胞、其构建方法、利用其的检测***和方法 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230691A (en) * | 1978-05-23 | 1980-10-28 | The Massachusetts General Hospital | Nerve growth factor antibody and process |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
SE465573B (sv) | 1989-03-14 | 1991-09-30 | Lope Medicine Ab | Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
CA2097309A1 (en) | 1990-11-30 | 1992-05-31 | Peter S. Distefano | Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0578515A3 (en) | 1992-05-26 | 1995-05-10 | Bristol Myers Squibb Co | Humanized monoclonal antibodies. |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
GB9402331D0 (en) * | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
AU783964B2 (en) | 1999-08-06 | 2006-01-05 | S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati | Non-human transgenic animals for the study of neurodegenerative syndromes |
US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
CA2448956C (en) | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
CA2500901A1 (en) * | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
MXPA05003502A (es) * | 2002-10-08 | 2005-09-30 | Rinat Neuroscience Corp | Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo. |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
AU2003304238A1 (en) * | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
AU2003286467B2 (en) * | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8066997B2 (en) * | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
NZ540730A (en) * | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
WO2004065560A2 (en) | 2003-01-18 | 2004-08-05 | Rinat Neuroscience Corp. | Methods of screening for modulators of nerve growth factor |
ATE491444T1 (de) * | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
CN1871028A (zh) * | 2003-02-19 | 2006-11-29 | 里纳特神经***学公司 | 通过施用神经生长因子拮抗剂和nsaid和含有它们的组合物治疗疼痛的方法 |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
WO2005044293A2 (en) | 2003-11-07 | 2005-05-19 | Lay Line Genomics S.P.A. | Compositions able to prevent neurodegenerative processes and methods of assaying the same |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
KR101504729B1 (ko) | 2004-04-07 | 2015-03-19 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물 |
ITRM20040212A1 (it) | 2004-04-30 | 2004-07-30 | Lay Line Genomics Spa | Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce. |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
US8911726B2 (en) * | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
KR101298383B1 (ko) * | 2005-01-24 | 2013-08-20 | 엘란 파마 인터내셔널 리미티드 | Ngf에 대한 특이적 결합 멤버 |
CA2606576A1 (en) | 2005-05-20 | 2006-11-23 | Lonza Biologics Plc. | High-level expression of recombinant antibody in a mammalian host cell |
ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー/エス | 安定なIgG4抗体 |
US8309088B2 (en) * | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
PT2187964E (pt) | 2007-08-10 | 2015-01-14 | Regeneron Pharma | Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano |
WO2009077993A2 (en) * | 2007-12-17 | 2009-06-25 | Pfizer Limited | Treatment of interstitial cystitis |
WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
PT2448970E (pt) * | 2009-05-04 | 2014-10-20 | Abbvie Res B V | Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada |
WO2011000020A1 (en) | 2009-06-12 | 2011-01-06 | Sbc Research Pty Ltd | Enhanced method of detection |
AU2011227335B2 (en) | 2010-03-17 | 2014-11-06 | Abbott Research B.V. | Anti-nerve growth factor (NGF) antibody compositions |
-
2010
- 2010-05-04 PT PT107308272T patent/PT2448970E/pt unknown
- 2010-05-04 ES ES10730827.2T patent/ES2514319T3/es active Active
- 2010-05-04 PL PL10730827T patent/PL2448970T3/pl unknown
- 2010-05-04 BR BRPI1014445A patent/BRPI1014445A8/pt not_active IP Right Cessation
- 2010-05-04 PE PE2011001896A patent/PE20121540A1/es not_active Application Discontinuation
- 2010-05-04 JP JP2012509110A patent/JP5898064B2/ja not_active Expired - Fee Related
- 2010-05-04 WO PCT/IB2010/001210 patent/WO2010128398A1/en active Application Filing
- 2010-05-04 SI SI201030768T patent/SI2448970T1/sl unknown
- 2010-05-04 RU RU2011149263/10A patent/RU2549679C2/ru not_active IP Right Cessation
- 2010-05-04 SG SG2011080512A patent/SG175436A1/en unknown
- 2010-05-04 CN CN201080027785.1A patent/CN102459337B/zh not_active Expired - Fee Related
- 2010-05-04 TW TW099114298A patent/TWI486171B/zh not_active IP Right Cessation
- 2010-05-04 UY UY0001032608A patent/UY32608A/es not_active Application Discontinuation
- 2010-05-04 NZ NZ596839A patent/NZ596839A/en not_active IP Right Cessation
- 2010-05-04 KR KR1020117028987A patent/KR20120088550A/ko not_active Application Discontinuation
- 2010-05-04 UA UAA201114294A patent/UA104890C2/uk unknown
- 2010-05-04 AU AU2010244133A patent/AU2010244133B2/en not_active Ceased
- 2010-05-04 EP EP10730827.2A patent/EP2448970B1/en active Active
- 2010-05-04 AR ARP100101512A patent/AR076650A1/es unknown
- 2010-05-04 DK DK10730827.2T patent/DK2448970T3/da active
- 2010-05-04 MX MX2011011728A patent/MX2011011728A/es active IP Right Grant
- 2010-05-04 US US12/773,488 patent/US8435523B2/en not_active Expired - Fee Related
- 2010-05-04 CA CA2761203A patent/CA2761203A1/en not_active Abandoned
-
2011
- 2011-11-03 IL IL216128A patent/IL216128A/en not_active IP Right Cessation
- 2011-11-04 CL CL2011002765A patent/CL2011002765A1/es unknown
- 2011-11-04 DO DO2011000337A patent/DOP2011000337A/es unknown
- 2011-11-24 CO CO11161350A patent/CO6470819A2/es not_active Application Discontinuation
- 2011-11-25 CR CR20110629A patent/CR20110629A/es unknown
- 2011-12-02 EC ECSP11011502 patent/ECSP11011502A/es unknown
-
2012
- 2012-11-09 HK HK12111320.4A patent/HK1170508A1/xx not_active IP Right Cessation
-
2013
- 2013-05-02 US US13/886,104 patent/US9447181B2/en not_active Expired - Fee Related
-
2014
- 2014-09-24 HR HRP20140915AT patent/HRP20140915T1/hr unknown
-
2015
- 2015-11-06 JP JP2015218598A patent/JP2016026221A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA104890C2 (uk) | Антитіла проти фактора росту нервів (фрн), що мають підвищену стабільність in vivo | |
Li et al. | Let-7 microRNAs regenerate peripheral nerve regeneration by targeting nerve growth factor | |
Son et al. | Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin | |
WO2008033413A3 (en) | Albumin fusion proteins | |
PH12020551039A1 (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
MX346923B (es) | Genes y proteinas para sintesis de alcanoil-coa. | |
CA2796465C (en) | Genes and proteins for aromatic polyketide synthesis | |
MX2011010989A (es) | Control de glicosilacion de proteina y composiciones y metodos que se refieren a la misma. | |
BR112012016043A2 (pt) | ''célula hospedeira de levedura recombinante, métodos para reproduzir isobutanol, para aumentar o consumo de glicose, para aumentar a formação de um produto de uma via biossintética e para melhorar o balanço de redox" | |
BRPI0821088A2 (pt) | construção de ácido nucléico, célula hospedeira microbiana transgênica, e, métodos para produzir um polipeptídeo tendo atividade de feruloil esterase, para produzir um mutante de uma célula-mãe, para inibir a expressão de um polipeptídeo tendo atividade de feruloil esterase em uma célula, para produzir uma proteína, e, para degradar um material contendo xilano. | |
WO2007021494A3 (en) | Albumin fusion proteins | |
MX2010003371A (es) | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. | |
WO2009086156A3 (en) | Mir-10 regulated genes and pathways as targets for therapeutic intervention | |
NZ597947A (en) | Klotho-beta for use in treating cancer, liver disorders, wasting syndrome and obesity-related diseases | |
MX2014001246A (es) | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. | |
BR112015022507A2 (pt) | ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados | |
WO2011106766A3 (en) | Modified proteins and methods of making and using same | |
MX362430B (es) | Enzima de enfermedad del almacenamiento lisosomico. | |
MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
ATE477337T1 (de) | Zusammensetzungen und verfahren zur sirna-hemmung von icam-1 | |
MX362028B (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
WO2009036933A3 (de) | Herabregulation der genexpression mittels nukleinsäure-beladener virusähnlicher partikel | |
WO2005079367A3 (en) | Schizochytrium fatty acid synthase (fas) and products and methods related thereto | |
IN2014CN04734A (uk) |